Fluorogenic tagging methodology applied to characterize oxidized tyrosine and phenylalanine in an immunoglobulin monoclonal antibody

Pharmaceutical Research

Volumn 30, Issue 5, 2013, Pages 1311-1327

  Zhou, Shuxia ^a   Mozziconacci, Olivier ^a   Kerwin, Bruce A ^b   Schöneich, Christian ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b AMGEN INC   (United States)

Author keywords

ABS fluorogenic tagging derivatization; immunoglobulin G (IgG) monoclonal antibody (mAb); metal catalyzed oxidation (MCO); protein degradation; reverse phase liquid chromatography with mass spectrometry (RPLC MS)

Indexed keywords

ASCORBIC ACID; BENZOXAZOLE DERIVATIVE; COPPER CHLORIDE; HISTIDINE; IMMUNOGLOBULIN G1; METHIONINE; MONOCLONAL ANTIBODY; OXIDIZED PHENYLALANINE; OXIDIZED TYROSINE; PHENYLALANINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; GEL PERMEATION CHROMATOGRAPHY; MASS SPECTROMETRY; OXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; REVERSED PHASE LIQUID CHROMATOGRAPHY; SPECTROFLUOROMETRY;

ASCORBIC ACID; BENZOXAZOLES; COPPER; IMMUNOGLOBULIN G; OXIDATION-REDUCTION; PHENYLALANINE; SPECTROMETRY, FLUORESCENCE; TYROSINE;

EID: 84876497784     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0970-7     Document Type: Article

References (36)

1. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2:52-62.
2. Bebbington C, Yarranton G. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol. 2008;19:613-9.
3. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5:147-59.
4. Bee JS, Nelson SA, Freund E, Carpenter JF, Randolph TW. Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci. 2009;98:3290-301.
5. Li S, Nguyen TH, Schöneich C, Borchardt RT. Aggregation and precipitation of human Relaxin induced by metal-catalyzed oxidation. Biochemistry. 1995;34:5762-72.
6. Li S, Schöneich C, Wilson GS, Borchardt RT. Chemical pathways of peptide degradation. V. ascorbic acid promotes rather than inhibits the oxidation of methionine to methionine sulfoxide in small model peptides. Pharm Res. 1993;10:1572-9.
7. Stadtman ER. Metal Ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med. 1990;9:315-25.
8. Stadtman ER. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem. 1993;62:797-821.
9. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular link between parkinson's disease and heavy metal exposure. J Biol Chem. 2001;276:44284-96.
10. Zhao F, Ghezzo-Schöneich E, Aced GI, Hong J, Milby T, Schöneich C. Metal-catalyzed oxidation of histidine in human growth hormone. mechanism, isotope effects, and inhibition by a mild denaturing alcohol. J Biol Chem. 1997;272:9019-29.
11. Zhou S, Zhang B, Sturm E, Teagarden DL, Schöneich C, Kolhe P, et al. Comparative evaluation of disodium edetate and diethylenetriaminepentaacetic acid as iron chelators to prevent metal-catalyzed destabilization of a therapeutic monoclonal antibody. J Pharm Sci. 2010;99:4239-50.
12. Schöneich C. Selective Cu2+/ascorbate-Dependent Oxidation of Alzheimer's Disease Beta-Amyloid Peptides. Ann N Y Acad Sci. 2004;1012:164-70.
13. Schöneich C. Mechanisms of metal-catalyzed oxidation of histidine to 2-oxo-Histidine in peptides and proteins. J Pharm Biomed Anal. 2000;21:1093-7.
14. Luo Q, Joubert MK, Stevenson R, Ketchem RR, Narhi LO, Wypych J. Chemical modifications in therapeutic protein aggregates generated under different stress conditions. J Biol Chem. 2011;286:25134-44.
15. Limand J, Vachet RW. Development of a methodology based on metal-catalyzed oxidation reactions and mass spectrometry to determine the metal binding sites in copper metalloproteins. Anal Chem. 2003;75:1164-72.
16. Schöneich C, Williams TD. Cu(II)-Catalyzed Oxidation of Beta-Amyloid Peptide Targets His13 and His14 over His6: Detection of 2-Oxo-Histidine by HPLC-MS/MS. Chem Res Toxicol. 2002;15:717-22.
17. Schöneich C, Williams TD. Cu(II)-Catalyzed Oxidation of Alzheimer's Disease Beta-Amyloid Peptide and Related Sequences: remarkably different selectivities of neurotoxic βAP1-40 and Non-Toxic βAP40-1. Cell Mol Biol. 2003;49:753-61.
18. Torosantucci R, Mozziconacci O, Sharov V, Schöneich C, Jiskoot W. Chemical Modifications in Aggregates of Recombinant Human Insulin Induced by Metal-Catalyzed Oxidation: covalent cross-linking via michael addition to tyrosine oxidation products. Pharm Res. 2012;29:2276-93.
19. Dubinina EE, Gavrovskaya SV, Kuzmich EV, Leonova NV, Morozova MG, Kovrugina SV, et al. Oxidative modification of proteins: oxidation of tryptophan and production of dityrosine in purified proteins using Fenton's system. Biochemistry. 2002;67:343-50.
20. Huggins TG, Wells-Knecht MC, Detorie NA, Baynes JW, Thorpe SR. Formation of o-Tyrosine and Dityrosine in Proteins During Radiolytic and Metal-Catalyzed Oxidation. J Biol Chem. 1993;268:12341-7.
21. Sharov VS, Dremina ES, Galeva NA, Gerstenecker GS, Li X, Dobrowsky RT, et al. Fluorogenic Tagging of Peptide and Protein 3-Nitrotyrosine with 4-(Aminomethyl)-benzenesulfonic Acid for Quantitative Analysis of Protein Tyrosine Nitration. Chromatographia. 2010;71:37-53.
22. Zhou S, Evans B, Schöneich C, Singh SK. Biotherapeutic Formulation Factors Affecting Metal Leachables from Stainless Steel Studied by Design of Experiments. AAPS PharmSciTech. 2012;13:284-94.
23. Zhou S, Schöneich C, Singh SK. Biologics Formulation Factors Affecting Metal Leachables from Stainless Steel. AAPS PharmSciTech. 2011;12:411-21.
24. Zhou S, Singh S, Lewis L. Metal Leachables in Therapeutic Biologic Products: Origin, Impact and Detection. Am Pharm Rev. 2010;13:76-80.
25. Ferrige AG, Seddon MJ, Green BN, Jarvis SA, Skilling J. Disentangling Electrospray Spectra with Maximum-Entropy. Rapid Commun Mass Spec. 1992;6:707-11.
26. Ferrige AG, Seddon MJ, Jarvis S. Maximum-Entropy Deconvolution in Electrospray Mass-Spectrometry. Rapid Commun Mass Spec. 1991;5:374-7.
27. Ferrige AG, Seddon MJ, Skilling J, Ordsmith N. The Application of Maxent to High-Resolution Mass-Spectrometry. Rapid Commun Mass Spec. 1992;6:765-70.
28. Shevchenko A, Wilm M, Vorm O, Mann M. Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels. Anal Chem. 1996;68:850-8.
29. Ikehata K, Duzhak TG, Galeva NA, Ji T, Koen YM, Hanzlik RP. Protein Targets of Reactive Metabolites of Thiobenzamide in Rat Liver in Vivo. Chem Res Toxicol. 2008;21:1432-42.
30. Xu H, Freitas MA. A Mass Accuracy Sensitive Probability Based Scoring Algorithm for Database Searching of Tandem Mass Spectrometry Data. BMC Bioinforma. 2007;8:133.
31. Xu H, Freitas MA. MassMatrix: a Database Search Program for Rapid Characterization of Proteins and Peptides from Tandem Mass Spectrometry Data. Proteomics. 2009;9:1548-55.
32. Xu H, Yang L, Freitas MA. A Robust Linear Regression Based Algorithm for Automated Evaluation of Peptide Identifications from Shotgun Proteomics by Use of Reversed-Phase Liquid Chromatography Retention Time. BMC Bioinforma. 2008;9:347.
33. Roepstorff P, Fohlman J. Proposal for a common nomenclature for sequence ions in mass spectra of peptides. Biomed Mass Spectrom. 1984;11:601.
34. Kaur H, Fagerheim I, Grootveld M, Puppo A, Halliwell B. Aromatic Hydroxylation of Phenylalanine as an Assay for Hydroxyl Radicals: Application to Activated Human Neutrophils and to the Heme Protein Leghemoglobin. Anal Biochem. 1988;172:360-7.
35. Shacter E. Quantification and Significance of Protein Oxidation in Biological Samples. Drug Metab Rev. 2000;32:307-26.
36. Schöneich C, Sharov VS. Mass Spectrometry of Protein Modifications by Reactive Oxygen and Nitrogen Species. Free Radic Biol Med. 2006;41:1507-20.